News

Chrono Therapeutics ropes in new funds from Rock Health for smoking cessation device

Chrono Therapeutics got a fresh infusion of cash from Rock Health to support development of its programmable monitoring system for smoking cessation.

FDA shoots down Pacira's bid for expanding Exparel

Pacira's hopes of expanding the use of its surgical pain drug took a hit this week, as the FDA rejected its application to get Exparel approved through a new delivery pathway.

Forbes gives drug delivery a shoutout, says it can make good drugs great

Drug delivery is proving to be a useful and economical source of innovation due to the difficulty and cost of finding new molecular drug candidates, Forbes says in its article, "Is the future of pharma about making good drugs great?"

Amgen launches delivery device for automatic administration of its blockbuster Neulasta

Amgen just announced the debut of the Neulasta Delivery Kit to automatically deliver the medication for infection prevention among cancer patients about 27 hours after chemotherapy, thereby ensuring compliance with the dosing instructions.

FDA requires new labeling on insulin pens to ward off spread of infections

The FDA is taking action to ensure that multidose insulin pens do not spread diseases by requiring the injectable devices to display the warning "For single patient use only."

Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D

Additional evidence that oxytocin increases eye contact among autistic patients adds urgency to the efforts of GlaxoSmithKline, OptiNose and other companies scrambling to develop an inhaled version of the "love hormone."

Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel

Prometheon Pharma says it has developed a breakthrough transdermal drug delivery system that can passively deliver large molecules like human growth hormone (which has a size of 2,200 daltons) across the skin.

WHO adopts new safety needle policy, calling smart syringes an 'urgent priority'

Citing rampant use of the same needle to inject more than one person, the World Health Organization has--some might say finally--launched a new policy to make unsafe injections less prevalent. Part of this policy involves adopting up-to-date measures in syringe engineering, promoting the use of "smart" needles with precautions against unsafe use.

MIT team injects drug-carrying hydrogel that 're-heals' in the body

A team of MIT scientists has designed a new injectable hydrogel made from nanoparticles that could someday be used to hold drugs in the body, treating diseases such as cancer, macular degeneration and heart disease.

OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates

Oncology company Heat Biologics is partnering with OncoSec, developer of the ImmunoPulse intratumoral DNA delivery platform. The two companies will evaluate the combination of the immunotherapy approaches developed by each company, according to the release.

UPDATED: FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug

Endo Pharmaceutical's investigational Belbuca buccal film strip for severe chronic pain has been accepted for review by the FDA, marking a win for the BioErodible MucoAdhesive technology to deliver drugs across mucosal surfaces like the inside of the cheek. And BEMA platform developer BioDelivery Sciences receives a $10 million milestone payment.

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.

Lupin inks two partnerships to bring lung drugs to overseas markets

Indian drugmaker Lupin announced two separate developments in its asthma drug delivery segment, launching one product in the U.S. and signing a development agreement for a generic version of GlaxoSmithKline's Advair Diskus, which would be commercialized in North America and other markets.

Developer of oral versions of biologic therapies to be purchased by Intrexon

Biotech player Intrexon has signed up to acquire Belgium's ActoGeniX for $60 million. The new addition is a developer of oral meds as an alternative to injectable biologics. Currently, biologic therapies cannot withstand the rigors of the acid in the stomach, so oral versions of the new-era drugs are lacking.

Study shows silicon drug carriers degrade faster at a tumor site

A new study from American and Israeli researchers has shown that nanostructures used to deliver cancer drugs act differently within the local area of a tumor than they do in healthy cells, a finding that could change the way these nanomaterials are made and how they target their drug release.

Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease

Rare disease specialist Genzyme talked up the results of a study published in The Journal of the American Medical Association concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.

Actavis divests its drug delivery unit as it barrels toward acquisition of Allergan

Saying it needs to focus on the looming integration effort with Botox maker Allergan, Actavis announced that it will sell Aptalis Pharmaceutical Technologies, a third-party supplier of drug delivery capsules and taste-masking formulations, back to private equity firm TPG for an undisclosed amount. The deal is expected to close in mid-2015.

UPDATED: FDA agrees to review Pfizer's abuse-deterring opioid candidate

Pharma bigwig Pfizer announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02.

The future: Biodegradable surgical tools to deliver drugs to remote parts of the body?

New materials could improve drug delivery by enabling the development of biodegradeable surgical tools that can safely dissolve in the body.

SteadyMed seeks $55M IPO to fund its drug delivery device, looks to upend United Therapeutics' Remodulin

Drug delivery specialist SteadyMed filed for a $55 million IPO to list on the Nasdaq, as it seeks to raise funds for its PatchPump drug delivery device to treat the orphan disease pulmonary arterial hypertension, or high blood pressure in the arteries of the lungs.